(Post-pandemic Era)-Global Nuclear Medicine/Radiopharmaceuticals Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026



  • As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.


    Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.

    In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.

    Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.

    Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research team published a report for global Nuclear Medicine/Radiopharmaceuticals market in this environment.


    In terms of revenue, this research report indicated that the global Nuclear Medicine/Radiopharmaceuticals market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Nuclear Medicine/Radiopharmaceuticals industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.


    The Cardinal Health aims at producing XX Nuclear Medicine/Radiopharmaceuticals in 2020, with XX % production to take place in global market, Mallinckrodt accounts for a volume share of XX %.


    Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Nuclear Medicine/Radiopharmaceuticals Market Include by

    China

    EU

    USA

    Japan

    India

    Southeast Asia

    South America

    Competitive Analysis; Who are the Major Players in Nuclear Medicine/Radiopharmaceuticals Market

    Cardinal Health

    Mallinckrodt

    GE Healthcare

    Lantheus Medical Imaging

    Bayer

    Bracco Imaging

    Eczacibasi-Monrol Nuclear Products

    Nordion

    Advanced Accelerator Applications

    IBA Molecular Imaging


    Major Type of Nuclear Medicine/Radiopharmaceuticals Covered in report:

    Diagnostic (SPECT - Technetium, PET - F-18)

    Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)

    Application Segments Covered in report

    Oncology

    Thyroid

    Cardiology


    For any other requirements, please feel free to contact us and we will provide you customized report.


     

  • With tables and figures helping analyze worldwide (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

    Global Nuclear Medicine/Radiopharmaceuticals Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate

    1 Market Scope

    1.1 Product Details and Introduction

    1.1.1 Diagnostic (SPECT - Technetium, PET - F-18) -Product Introduction and Major Manufacturers
    1.1.2 Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) -Product Introduction and Major Manufacturers

    1.2 Market Snapshot

    1.2.1 Major Companies Overview
    1.2.2 Market Concentration
    1.2.3 Six-Year Compound Annual Growth Rate (CAGR)

    2 Global Nuclear Medicine/Radiopharmaceuticals Market Assessment, by Segmentation

    2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)

    2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)

    2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)


    3 Regional Market Analysis

    3.1 China Nuclear Medicine/Radiopharmaceuticals Market

    3.1.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in China (2015-2020)
    3.1.2 Sales Value of Major Company in China Market (2015-2020)
    3.1.3 China Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.1.4 Sales in China Market, by Type (2015-2026)

    3.2 EU Nuclear Medicine/Radiopharmaceuticals Market

    3.2.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in EU (2015-2020)
    3.2.2 Sales Value of Major Company in EU Market (2015-2020)
    3.2.3 EU Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.2.4 Sales in EU Market, by Type (2015-2026)

    3.3 USA Nuclear Medicine/Radiopharmaceuticals Market

    3.3.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in USA (2015-2020)
    3.3.2 Sales Value of Major Company in USA Market (2015-2020)
    3.3.3 USA Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.3.4 Sales in USA Market, by Type (2015-2026)

    3.4 Japan Nuclear Medicine/Radiopharmaceuticals Market

    3.4.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in Japan (2015-2020)
    3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
    3.4.3 Japan Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.4.4 Sales in Japan Market, by Type (2015-2026)

    3.5 India Nuclear Medicine/Radiopharmaceuticals Market

    3.5.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in India (2015-2020)
    3.5.2 Sales Value of Major Company in India Market (2015-2020)
    3.5.3 India Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.5.4 Sales in India Market, by Type (2015-2026)

    3.6 Southeast Asia Nuclear Medicine/Radiopharmaceuticals Market

    3.6.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in Southeast Asia (2015-2020)
    3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
    3.6.3 Southeast Asia Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
    3.7 South America Nuclear Medicine/Radiopharmaceuticals Market
    3.7.1 Top Companies leading Nuclear Medicine/Radiopharmaceuticals Development in South America (2015-2020)
    3.7.2 Sales Value of Major Company in South America Market (2015-2020)
    3.7.3 South America Nuclear Medicine/Radiopharmaceuticals Price (USD/Unit), by Type (2019-2020)
    3.7.4 Sales in South America Market, by Type (2015-2026)

    4 Value Chain (Impact of COVID-19)

    4.1 Nuclear Medicine/Radiopharmaceuticals Value Chain Analysis

    4.1.1 Upstream
    4.1.2 Downstream

    4.2 COVID-19 Impact on Nuclear Medicine/Radiopharmaceuticals Industry

    4.2.1 Industrial Policy Issued Under the Epidemic Situation

    4.3 Cost-Under the Epidemic Situation

    4.3.1 Cost of Raw Material

    4.4 Channel Analysis

    4.4.1 Distribution Channel-Under the Epidemic Situation
    4.4.2 Distributors

    5 Regional Market Forecast (2021-2026)

    5.1 Global Nuclear Medicine/Radiopharmaceuticals Sales and Growth Rate (2021-2026)

    5.2 Global Nuclear Medicine/Radiopharmaceuticals Sales Value and Growth Rate (2021-2026)


    6 Nuclear Medicine/Radiopharmaceuticals Competitive Analysis

    6.1 Cardinal Health

    6.1.1 Cardinal Health Company Profiles
    6.1.2 Cardinal Health Product Introduction
    6.1.3 Cardinal Health Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.1.4 SWOT Analysis

    6.2 Mallinckrodt

    6.2.1 Mallinckrodt Company Profiles
    6.2.2 Mallinckrodt Product Introduction
    6.2.3 Mallinckrodt Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.2.4 SWOT Analysis

    6.3 GE Healthcare

    6.3.1 GE Healthcare Company Profiles
    6.3.2 GE Healthcare Product Introduction
    6.3.3 GE Healthcare Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.3.4 SWOT Analysis

    6.4 Lantheus Medical Imaging

    6.4.1 Lantheus Medical Imaging Company Profiles
    6.4.2 Lantheus Medical Imaging Product Introduction
    6.4.3 Lantheus Medical Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.4.4 SWOT Analysis

    6.5 Bayer

    6.5.1 Bayer Company Profiles
    6.5.2 Bayer Product Introduction
    6.5.3 Bayer Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.5.4 SWOT Analysis

    6.6 Bracco Imaging

    6.6.1 Bracco Imaging Company Profiles
    6.6.2 Bracco Imaging Product Introduction
    6.6.3 Bracco Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.6.4 SWOT Analysis
    6.7 Eczacibasi-Monrol Nuclear Products
    6.7.1 Eczacibasi-Monrol Nuclear Products Company Profiles
    6.7.2 Eczacibasi-Monrol Nuclear Products Product Introduction
    6.7.3 Eczacibasi-Monrol Nuclear Products Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.7.4 SWOT Analysis
    6.8 Nordion
    6.8.1 Nordion Company Profiles
    6.8.2 Nordion Product Introduction
    6.8.3 Nordion Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.8.4 SWOT Analysis
    6.9 Advanced Accelerator Applications
    6.9.1 Advanced Accelerator Applications Company Profiles
    6.9.2 Advanced Accelerator Applications Product Introduction
    6.9.3 Advanced Accelerator Applications Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.9.4 SWOT Analysis

    6.10 IBA Molecular Imaging

    6.10.1 IBA Molecular Imaging Company Profiles
    6.10.2 IBA Molecular Imaging Product Introduction
    6.10.3 IBA Molecular Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
    6.10.4 SWOT Analysis

    7 Conclusion

     

  • The (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

    Report Objectives / Segmentation Covered :
    By Companies / players:
      By Regions:
        By Type:
          By Application:
          Frequently asked questions(FAQ's):
          What trends are influencing the growth of the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market?

          New players are entering the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.

          What are the major applications for (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals?

          (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals has a wide range of applications, including and others.

          How big is the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market by 2030?

          It is expected that the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market will reach USD XX million by 2030.

          Is further segmentation possible given the scope of the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market study?

          Yes, the add-on segmentation is available in the premium customised version of the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market report for a more in-depth analysis. It aids in the calculation of refined and precise market values.

          What are the primary data sources used to evaluate the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Market sizing?

          The majority of data for the (Post pandemic Era) Global Nuclear Medicine Radiopharmaceuticals Industry is gathered through primary sources, which include interviews and surveys with industry experts from the core and related industries involved in the supply chain. Secondary sources, such as SEC filings, annual reports, whitepapers, and press releases, are also used.

          Our Clients